MedPath

Dampening the Reproductive Axis With Continuous Kisspeptin

Phase 1
Recruiting
Conditions
Reproductive Disorder
PCOS
Polycystic Ovary Syndrome
Interventions
Registration Number
NCT05971849
Lead Sponsor
Stephanie B. Seminara, MD
Brief Summary

The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).

Detailed Description

Assignment: All study subjects will undergo the same interventions. Baseline LH secretion patterns of individuals with PCOS will be compared to their LH secretion patterns while receiving a kisspeptin infusion.

Delivery of Interventions:

* Prior to the inpatient study visit, the subjects will undergo a review of their medical history, physical exam, and screening laboratories.

* On the day of the study, the subjects will have an intravenous (IV) line placed and

* Undergo up to q10 min blood sampling x 36 hours

* Receive an infusion of kisspeptin x 24 hours

* Receive up to two kisspeptin IV boluses

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
4
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
kisspeptinkisspeptin 112-121IV administration of kisspeptin 112-121; 24-hour infusion, up to 2 boluses.
Primary Outcome Measures
NameTimeMethod
Average change in LH pulse frequency6 hours prior to kisspeptin infusion compared to the final 6 hours of kisspeptin infusion

Average change in LH pulse frequency before and during kisspeptin infusion

Average change in LH pulse amplitude6 hours prior to kisspeptin infusion compared to the final 6 hours of kisspeptin infusion

Average change in LH pulse amplitude before and during kisspeptin infusion

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath